

# TSUNAMI Newsletter -- April 2009

## 116<sup>th</sup> Business Plan Presentations held on April 8, 2009 at Iwasaki Gakuen in Yokohama

### 1. ACS Inc. <http://www.agrebe.com> (Japanese)

**President (Mr. Koji Komura)** Established in August 2008 Capital stock: 4 million yen  
ASC has a patent license for reusable bedding for test animals, and develops business based on this license around Agrebe, a fabric bedding material which delivers a weak-acid maintenance performance. While discardable wood shavings are still the main type of bedding, their replacement with this reusable type brings a big reduction in the amount of waste from laboratories as well as a decrease in dirt and improvement of the cage environment for the animals. As such, it also mitigates load factors in test data and the facility environment. Agrebe is the only practical reusable bedding. The spread of this system would presumably enable the company to make exclusive inroads into the market. It plans to fill out its assortment of related products and expand this business while pursuing more orders for outsourced washing work.



Mr. Komura

【Re-cap】 I was amazing to learn that some 1.3 million square meters of forest land are logged every year just to get bedding for test animals (mice and rats) in Japan. Paper bedding, too, has a lot of drawbacks, including the scattering of dirt. Agrebe is a washable material, and minimizes waste and dirt. This seems as an ideal choice for both the keepers and the rodents, and appears to have good prospects for use by companies and laboratories in fields such as pharmaceuticals and food products.

### 2. BioMedCore Inc. <http://www.bmcore.co.jp/> (Japanese)

**President (Mr. Yuichiro Sato)** Established in December 2005 Capital stock: 75 million yen  
BioMedCore hopes to supply innovative pharmaceuticals and treatment technology for cancer and infectious diseases. Its core technology consists of revolutionary active-targeting drug delivery system (DDS) devices, mannose-sheathed liposomes enabling application as TH1 vaccine adjuvants, and an innovative manufacturing process for liposomes that is both cost-competitive and of a general-purpose nature. It has also launched business in outsourced manufacture of devices (liposomes). Together with partners in the DDS and vaccine fields as well as manufacturing equipment engineering firms, it is working to extend its business to cosmetics, pharmaceuticals, sphere of industrial products such as cosmetics, animal agents, reagents and even industrial products such as coatings.



Mr. Sato

【Re-cap】 BioMedCore was founded for new drug creation through use of nano-targeting devices. In this presentation, however, BioMedCore talked about its business in outsourced manufacture of liposomes applying its platform technology. It has perfected an innovative manufacturing process, and utilization of the same could very well drive an expansion of its business not only in the field of pharmaceuticals but also in those of health foods and cosmetics, and further to those of paints and other industrial products.

### 3. Tsukuba Seiko Corp. <http://www.tsukubaseiko.co.jp/> (Japanese)

**President (Mr. Hisashi Kakizaki)** Established in June 1985 Capital stock: 150 million yen  
Tsukuba Seiko's Seiden Chakku system enables electrostatic adsorption to a wide range of subjects, from large-scale LC glass substrates, high-performance film, wafers, and other semiconductor items to insulators. It develops, manufactures, and sells this technology, which resolves problems such as transfer of the adsorption hole occurring with vacuum pads and tables as well as marks left after adsorption, and delivers a stable performance even in vacuums or other special environments.



Mr. Kakizaki

【Re-cap】 The presentation reconfirmed the importance of Seiden Chaku technology for electrostatic adsorption, which is particularly indispensable in the semiconductor field, because it offers a uniform action on the entire subject surface and applicability for thin pieces. The company's assortment includes products for solar cells, which are attracting so much attention these days, as well as liquid crystal and organic electroluminescent (EL) devices. It is reportedly also designing different electrodes to match subject shapes.

### 4. EAMEX Corp. [http://www.eamex.co.jp/index\\_e.html](http://www.eamex.co.jp/index_e.html) (English)

**President (Mr. Shingo Sewa)** Established in August 2001 Capital stock: 445 million yen  
An R&D-oriented firm, EAMEX engages in research and development of high-polymer actuators, and applies the results to create a wide range of electro-mechanical device products together with clients. In parallel with its actuator development, it has been developing large-capacity capacitors. Recently, it prepared a device with an energy density of 100 Wh/L and output density of 5,000 Wh/L. It has already embarked on a program of joint development with a major company, and looks to have a bright future ahead.



Mr. Sewa

【Re-cap】 This presentation was EAMEX's third at the Tsunami Business Plan Presentation, and they informed all that it is going to start mass production during fiscal 2009. It is currently involved in a project for application development with a major Japanese firm in various fields, and has begun to sell mass-production samples. Its technology is required for diverse equipment, including catheters, endoscopes, drive devices, sensors/robots and toys.

In Japan, April brings the start of the new fiscal year as well as lovely cherry blossoms. We were gratified to see so many people again at the presentation meeting. We have the deepest respect for the management and staff of venture firms that are doing their utmost in these days of tough economic circumstances. We, too, are determined to keep providing such a presentation platform that is genuinely worthwhile for all concerned, and ask for your continued support in these efforts.

NPO Venture Support mechanism TSUNAMI  
(TEL: +81-45-470-8668 Yokohama, JAPAN)  
TSUNAMI Network Partners/ TNP On the Road  
(TEL: +81-45-470-8088)